TY - JOUR T1 - Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management JF - Anticancer Research JO - Anticancer Res SP - 2697 LP - 2702 VL - 37 IS - 5 AU - JIRI PRESL AU - PETRA OVESNA AU - ZDENEK NOVOTNY AU - PAVEL VLASAK AU - JIRI BOUDA AU - JAN KOSTUN AU - ONDREJ TOPOLCAN AU - RADEK KUCERA AU - MARKETA BEDNARIKOVA AU - VIT WEINBERGER Y1 - 2017/05/01 UR - http://ar.iiarjournals.org/content/37/5/2697.abstract N2 - Aim: To analyze the utility of HE4 assessment in preoperative management of patients with early-stage endometrial cancer for stratification into low-risk and high-risk groups. Patients and Methods: The following data were prospectively collected from patients operated for endometrial cancer from 05/2012 till 9/2016; age, HE4, CA125, expert ultrasound examination of the pelvis, histotype, grade, FIGO stage. Results: In total, 124 patients were enrolled. A cut-off of ≥113 pmol/l HE4 demonstrated 40.3% sensitivity and 83.9% specificity for detection of high-risk patients. Correlations of HE4 with age (p<0.001), depth of myometrial invasion (p=0.001), clinical stage of the disease according to ultrasound - T1a vs. T1b (63.6 pmol/l vs. 110.6 pmol/l, p<0.001) were found. However, no correlation of HE4 with lymph node invasion (p=0.07) and tumor grade (p=0.212) was identified. Conclusion: HE4 levels correspond to clinical and FIGO stage of the disease. The sensitivity and specificity does not reach the transvaginal ultrasound results in preoperative assessment of the extent of the disease. Combination of HE4 with ultrasound does not improve the stratification of patients into low-risk and high-risk groups. Preoperative assessment of HE4 is useful providing no imaging method is available. ER -